步长制药：全资子公司获磷酸奥司他韦胶囊药品注册证书

Core Viewpoint - Company announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate for Oseltamivir Phosphate Capsules from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The approved drug is primarily used for the treatment of influenza A and B in adults and children aged 1 year and older, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and older [1] Group 2: Market Potential - The annual sales figures for urban retail pharmacies in China for the years 2022, 2023, and 2024 are projected to be 152 million, 824 million, and 776 million respectively, indicating a growing market for influenza treatments [1] - The company has invested approximately 12.96 million in research and development for this project as of the announcement date [1]